Home

Explore NIH Technologies

Explore work by over 1,500 NIH researchers   |   Available for Licensing & Collaboration

 
NIH inventors have developed the first known method of producing Regulatory B-cells (Bregs) ex-vivo. There is a great need to supplement the low population of Bregs in a patient suffering from an autoimmune disease where Breg levels are severely reduced, such as uveitis. This method involves
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
Register to attend a free NIH webinar on Wednesday January 28, 2026 at 11am ET. Attendees will learn about a new AI enhanced real-time echocardiography device and method to improve the analysis and quantification of heart related conditions, by automatically extracting predictive biomarkers from an

Explore Featured Research

Get updates on the latest and most exciting research coming out of NIH...

Read More >

Explore Featured Products

Novel and interesting products coming to market through NIH inventions and partnerships...

Read More >